Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
- PMID: 20210985
- PMCID: PMC2851702
- DOI: 10.1186/1471-2288-10-18
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
Abstract
Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.
Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.
Results: A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.
Conclusion: Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Figures




Similar articles
-
A modified dose-response model that describes the relationship between haemagglutination inhibition titre and protection against influenza infection.J Appl Microbiol. 2018 Jan;124(1):294-301. doi: 10.1111/jam.13628. Epub 2017 Dec 7. J Appl Microbiol. 2018. PMID: 29112316
-
Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.HIV Med. 2012 Jul;13(6):352-7. doi: 10.1111/j.1468-1293.2011.00987.x. Epub 2012 Feb 2. HIV Med. 2012. PMID: 22296264
-
Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.Vaccine. 2015 Dec 8;33(49):7015-21. doi: 10.1016/j.vaccine.2015.09.016. Epub 2015 Sep 19. Vaccine. 2015. PMID: 26387434
-
Haemagglutination-inhibiting antibody to influenza virus.Dev Biol (Basel). 2003;115:63-73. Dev Biol (Basel). 2003. PMID: 15088777 Review.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
Repeated influenza vaccination induces similar immune protection as first-time vaccination but with differing immune responses.Influenza Other Respir Viruses. 2023 Jan;17(1):e13060. doi: 10.1111/irv.13060. Epub 2022 Oct 21. Influenza Other Respir Viruses. 2023. PMID: 36271687 Free PMC article.
-
Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.Hum Vaccin Immunother. 2015;11(8):1983-90. doi: 10.1080/21645515.2015.1011987. Hum Vaccin Immunother. 2015. PMID: 25746201 Free PMC article.
-
Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.Microb Pathog. 2013 Feb;55:9-15. doi: 10.1016/j.micpath.2012.11.013. Epub 2012 Dec 13. Microb Pathog. 2013. PMID: 23247146 Free PMC article. Review.
-
The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine.Vaccines (Basel). 2018 May 17;6(2):27. doi: 10.3390/vaccines6020027. Vaccines (Basel). 2018. PMID: 29772781 Free PMC article.
-
Evaluation of multivalent H2 influenza pandemic vaccines in mice.Vaccine. 2017 Mar 7;35(10):1455-1463. doi: 10.1016/j.vaccine.2017.01.026. Epub 2017 Feb 8. Vaccine. 2017. PMID: 28189402 Free PMC article.
References
-
- WHO. Factsheet number 211. World Health Organization; 2008. Influenza factsheet.http://www.who.int/mediacentre/factsheets/fs211/en/index.html 14-3-2008.
-
- Palmer DF, Dowdle WR, Coleman MT, Schild GC. Advanced laboratory technicals for immunological diagnostic. US Department of Health; 1975.
-
- Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. EMEA. 1997.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical